Industry in brief | Futura Medical, Alliance Pharma
15 April 2021
Futura Medical has reported its annual results, and Alliance Pharma is losing a non-executive director.
Industry News - Tag: Alliance Pharma
You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
Alliance Pharma reports mixed results in 2020
Premium
21 January 2021
Alliance Pharma said its Consumer Healthcare business had “performed well given the market backdrop” in 2020, with sales up by 1%. By contrast, the UK-based company’s Prescription Medicines business reported sales down by 14% due to the COVID-19 pandemic.
Alliance acquires Biogix and its Amberen brand
Premium
30 December 2020
Alliance Pharma has strengthened its consumer healthcare presence in the US by acquiring Biogix, including its Amberen brand, for USD110 million in cash.
Alliance Pharma creates Consumer Healthcare unit
Premium
24 September 2020
Alliance Pharma has divided its product portfolio into Consumer Healthcare brands and Prescription Medicines. The company said the Consumer Healthcare business generated sales of GBP43.8 million (USD55.8 million) in the first half of 2020, representing 67% of its total sales.
Alliance Pharma wants more consumer acquisitions
Premium
24 September 2020
Alliance Pharma remains keen to build its consumer healthcare presence through acquisitions, according to chief executive officer Peter Butterfield.
Alliance Pharma sees sales drop 7% amid COVID-19
Premium
24 July 2020
Alliance Pharma reported sales down by 7% in the first half of 2020 as its prescription medicines business was affected by the COVID-19 pandemic. The UK-based company said sales of its consumer healthcare products “continued to be robust”.
Industry in brief | Alliance Pharma and Church & Dwight
25 March 2020
Alliance Pharma and Church & Dwight have issued statements on the potential financial impact of the COVID-19 pandemic.
Alliance Pharma is “well placed” for more deals
Premium
23 January 2020
Alliance Pharma is “well placed to selectively add to its portfolio”, according to chief executive officer Peter Butterfield, who says the UK-based company is focusing on “augmenting its consumer brands in international markets”.